アトピー性皮膚炎治療薬のグローバル市場2023~2027:経口、外用、注射

【英語タイトル】Global Atopic Dermatitis Drugs Market 2023-2027

Technavioが出版した調査資料(IRTNTR75242-23)・商品コード:IRTNTR75242-23
・発行会社(調査会社):Technavio
・発行日:2023年4月18日
・ページ数:約120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:北米、ヨーロッパ、アジア、その他地域
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Technavio社の調査レポートによると、世界のアトピー性皮膚炎治療薬市場規模が、予測期間中(2022-2027年)にCAGR 9.28%増加し、4,720.19百万ドルへ到達すると推測されています。本レポートでは、アトピー性皮膚炎治療薬の世界市場を総合的に調査・分析を行い、エグゼクティブサマリー、市場状況、市場規模・予測、過去の市場規模、ファイブフォース分析、投与経路別(経口、外用、注射)分析、薬剤クラス別(生物製剤、PDE4阻害剤、副腎皮質ステロイド、カルシニューリン阻害剤)分析、顧客状況、地域別(北米、ヨーロッパ、アジア、その他地域、アメリカ、カナダ、ドイツ、イギリス、中国)分析、成長要因・課題・動向、企業状況、企業分析などの内容をまとめています。並びに、市場調査の対象企業には、AbbVie Inc.、Arcutis Biotherapeutics Inc.、Asana BioSciences LLC、Astellas Pharma Inc.、Bausch Health Co. Inc.、Bayer AG、Bristol Myers Squibb Co.、Dermavant Sciences Inc.、Eli Lilly and Co.、Evelo Biosciences Inc.、Galderma SA、Incyte Corp.などが含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模・予測
・過去の市場規模
・ファイブフォース分析
・世界のアトピー性皮膚炎治療薬市場規模:投与経路別
- 経口アトピー性皮膚炎治療薬の市場規模
- 外用アトピー性皮膚炎治療薬の市場規模
- 注射アトピー性皮膚炎治療薬の市場規模
・世界のアトピー性皮膚炎治療薬市場規模:薬剤クラス別
- 生物製剤の市場規模
- PDE4阻害剤の市場規模
- 副腎皮質ステロイドの市場規模
- カルシニューリン阻害剤の市場規模
・顧客状況
・世界のアトピー性皮膚炎治療薬市場規模:地域別
- 北米のアトピー性皮膚炎治療薬市場規模
- ヨーロッパのアトピー性皮膚炎治療薬市場規模
- アジアのアトピー性皮膚炎治療薬市場規模
- その他地域のアトピー性皮膚炎治療薬市場規模
- アメリカのアトピー性皮膚炎治療薬市場規模
- カナダのアトピー性皮膚炎治療薬市場規模
- ドイツのアトピー性皮膚炎治療薬市場規模
- イギリスのアトピー性皮膚炎治療薬市場規模
- 中国のアトピー性皮膚炎治療薬市場規模
・成長要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益・価格・競争・プロモーションなどの肝要な変数の分析をし、多種の情報源からのデータを調査、統合、および総括することにより、アトピー性皮膚炎治療薬市場の明細な全容を示します。主要産業のインフルエンサーを限定することにより、市場の様々な側面を提示します。提示されたデータは包括的​​で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査レポートは、正確なアトピー性皮膚炎治療薬市場の成長を推測するための定性的および定量的調査を使用し、完全な競争状況と詳細なベンダー選定手法と分析を提供します。

アトピー性皮膚炎治療薬の世界市場 2023-2027

Technavio社は、アトピー性皮膚炎治療薬市場をモニターしており、2022年から2027年にかけて4,720.19百米ドルの成長が予測され、予測期間中のCAGRは9.28%で加速すると予測しています。当レポートでは、アトピー性皮膚炎治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを提供しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。アトピー性皮膚炎の高い有病率、医療費の増加、強力な研究開発パイプラインが市場を牽引しています。

Technavio社のアトピー性皮膚炎治療薬市場は以下のように分類されます:

・投与経路別:
– 経口剤
– 外用薬
– 注射剤

・薬剤クラス別:
– 生物製剤
– PDE4阻害薬
– コルチコステロイド
– カルシニューリン阻害剤

・地域別:
– 北米
– ヨーロッパ
– アジア
– その他の地域(ROW)

本調査では、今後数年間のアトピー性皮膚炎治療薬市場の成長を促進する主な要因の一つとして、戦略的パートナーシップと買収を挙げています。また、地政学的な不確実性やアトピー性皮膚炎の認知度を高めるためのプログラムは、市場の大きな需要につながるでしょう。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

アトピー性皮膚炎治療薬市場に関する弊社の調査レポートは以下の分野をカバーしています:
– アトピー性皮膚炎治療薬市場のサイジング
– アトピー性皮膚炎治療薬市場予測
– アトピー性皮膚炎治療薬市場の産業分析

Technavioの強力なベンダー分析は、お客様が市場での地位を向上できるように設計されており、これに沿って本レポートには、AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Co. Inc., Bayer AG, Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Viatris Inc., and BiomX Incなどの企業情報が含まれています。また、アトピー性皮膚炎治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を練り、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。
Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global atopic dermatitis drugs market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on global atopic dermatitis drugs market 2017 – 2021 ($ million)
o 4.2 Route of Administration Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
o 4.3 Drug Class Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Drug Class Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Oral – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oral – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
o 6.4 Topical – Market size and forecast 2022-2027
o Exhibit 38: Chart on Topical – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Topical – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Topical – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Topical – Year-over-year growth 2022-2027 (%)
o 6.5 Injectable – Market size and forecast 2022-2027
o Exhibit 42: Chart on Injectable – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Injectable – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Injectable – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Injectable – Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by Route of Administration
o Exhibit 46: Market opportunity by Route of Administration ($ million)
o Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Drug Class
o 7.1 Market segments
o Exhibit 48: Chart on Drug Class – Market share 2022-2027 (%)
o Exhibit 49: Data Table on Drug Class – Market share 2022-2027 (%)
o 7.2 Comparison by Drug Class
o Exhibit 50: Chart on Comparison by Drug Class
o Exhibit 51: Data Table on Comparison by Drug Class
o 7.3 Biologics – Market size and forecast 2022-2027
o Exhibit 52: Chart on Biologics – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Biologics – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Biologics – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Biologics – Year-over-year growth 2022-2027 (%)
o 7.4 PDE4 inhibitors – Market size and forecast 2022-2027
o Exhibit 56: Chart on PDE4 inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on PDE4 inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on PDE4 inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on PDE4 inhibitors – Year-over-year growth 2022-2027 (%)
o 7.5 Corticosteroids – Market size and forecast 2022-2027
o Exhibit 60: Chart on Corticosteroids – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Corticosteroids – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Corticosteroids – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Corticosteroids – Year-over-year growth 2022-2027 (%)
o 7.6 Calcineurin inhibitors – Market size and forecast 2022-2027
o Exhibit 64: Chart on Calcineurin inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Data Table on Calcineurin inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Chart on Calcineurin inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 67: Data Table on Calcineurin inhibitors – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Drug Class
o Exhibit 68: Market opportunity by Drug Class ($ million)
o Exhibit 69: Data Table on Market opportunity by Drug Class ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 71: Chart on Market share by geography 2022-2027 (%)
o Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 73: Chart on Geographic comparison
o Exhibit 74: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 75: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 79: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 83: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 87: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 91: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 95: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 UK – Market size and forecast 2022-2027
o Exhibit 103: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.11 China – Market size and forecast 2022-2027
o Exhibit 107: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 108: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 109: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 110: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 111: Market opportunity by geography ($ million)
o Exhibit 112: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 113: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 115: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 116: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 117: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 118: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 119: AbbVie Inc. – Overview
o Exhibit 120: AbbVie Inc. – Product / Service
o Exhibit 121: AbbVie Inc. – Key news
o Exhibit 122: AbbVie Inc. – Key offerings
o 12.4 Arcutis Biotherapeutics Inc.
o Exhibit 123: Arcutis Biotherapeutics Inc. – Overview
o Exhibit 124: Arcutis Biotherapeutics Inc. – Product / Service
o Exhibit 125: Arcutis Biotherapeutics Inc. – Key offerings
o 12.5 Bausch Health Co. Inc.
o Exhibit 126: Bausch Health Co. Inc. – Overview
o Exhibit 127: Bausch Health Co. Inc. – Business segments
o Exhibit 128: Bausch Health Co. Inc. – Key news
o Exhibit 129: Bausch Health Co. Inc. – Key offerings
o Exhibit 130: Bausch Health Co. Inc. – Segment focus
o 12.6 Bristol Myers Squibb Co.
o Exhibit 131: Bristol Myers Squibb Co. – Overview
o Exhibit 132: Bristol Myers Squibb Co. – Product / Service
o Exhibit 133: Bristol Myers Squibb Co. – Key news
o Exhibit 134: Bristol Myers Squibb Co. – Key offerings
o 12.7 Eli Lilly and Co.
o Exhibit 135: Eli Lilly and Co. – Overview
o Exhibit 136: Eli Lilly and Co. – Product / Service
o Exhibit 137: Eli Lilly and Co. – Key offerings
o 12.8 Evelo Biosciences Inc.
o Exhibit 138: Evelo Biosciences Inc. – Overview
o Exhibit 139: Evelo Biosciences Inc. – Product / Service
o Exhibit 140: Evelo Biosciences Inc. – Key offerings
o 12.9 Galderma SA
o Exhibit 141: Galderma SA – Overview
o Exhibit 142: Galderma SA – Product / Service
o Exhibit 143: Galderma SA – Key news
o Exhibit 144: Galderma SA – Key offerings
o 12.10 Incyte Corp.
o Exhibit 145: Incyte Corp. – Overview
o Exhibit 146: Incyte Corp. – Product / Service
o Exhibit 147: Incyte Corp. – Key offerings
o 12.11 LEO Pharma AS
o Exhibit 148: LEO Pharma AS – Overview
o Exhibit 149: LEO Pharma AS – Business segments
o Exhibit 150: LEO Pharma AS – Key offerings
o Exhibit 151: LEO Pharma AS – Segment focus
o 12.12 Maruho Co. Ltd.
o Exhibit 152: Maruho Co. Ltd. – Overview
o Exhibit 153: Maruho Co. Ltd. – Product / Service
o Exhibit 154: Maruho Co. Ltd. – Key offerings
o 12.13 Novartis AG
o Exhibit 155: Novartis AG – Overview
o Exhibit 156: Novartis AG – Business segments
o Exhibit 157: Novartis AG – Key offerings
o Exhibit 158: Novartis AG – Segment focus
o 12.14 Otsuka Holdings Co. Ltd.
o Exhibit 159: Otsuka Holdings Co. Ltd. – Overview
o Exhibit 160: Otsuka Holdings Co. Ltd. – Business segments
o Exhibit 161: Otsuka Holdings Co. Ltd. – Key offerings
o Exhibit 162: Otsuka Holdings Co. Ltd. – Segment focus
o 12.15 Pfizer Inc.
o Exhibit 163: Pfizer Inc. – Overview
o Exhibit 164: Pfizer Inc. – Product / Service
o Exhibit 165: Pfizer Inc. – Key news
o Exhibit 166: Pfizer Inc. – Key offerings
o 12.16 Sanofi SA
o Exhibit 167: Sanofi SA – Overview
o Exhibit 168: Sanofi SA – Business segments
o Exhibit 169: Sanofi SA – Key news
o Exhibit 170: Sanofi SA – Key offerings
o Exhibit 171: Sanofi SA – Segment focus
o 12.17 Viatris Inc.
o Exhibit 172: Viatris Inc. – Overview
o Exhibit 173: Viatris Inc. – Business segments
o Exhibit 174: Viatris Inc. – Key offerings
o Exhibit 175: Viatris Inc. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 176: Inclusions checklist
o Exhibit 177: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 178: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 179: Research methodology
o Exhibit 180: Validation techniques employed for market sizing
o Exhibit 181: Information sources
o 13.5 List of abbreviations
o Exhibit 182: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary – Chart on Market Segmentation by Drug Class
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on global atopic dermatitis drugs market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Drug Class Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oral – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Topical – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Topical – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Topical – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Topical – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Injectable – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Injectable – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Injectable – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Injectable – Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Route of Administration ($ million)
Exhibits47: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits48: Chart on Drug Class – Market share 2022-2027 (%)
Exhibits49: Data Table on Drug Class – Market share 2022-2027 (%)
Exhibits50: Chart on Comparison by Drug Class
Exhibits51: Data Table on Comparison by Drug Class
Exhibits52: Chart on Biologics – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Biologics – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Biologics – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Biologics – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on PDE4 inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on PDE4 inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on PDE4 inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on PDE4 inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Corticosteroids – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Corticosteroids – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Corticosteroids – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Corticosteroids – Year-over-year growth 2022-2027 (%)
Exhibits64: Chart on Calcineurin inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits65: Data Table on Calcineurin inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits66: Chart on Calcineurin inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits67: Data Table on Calcineurin inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits68: Market opportunity by Drug Class ($ million)
Exhibits69: Data Table on Market opportunity by Drug Class ($ million)
Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits71: Chart on Market share by geography 2022-2027 (%)
Exhibits72: Data Table on Market share by geography 2022-2027 (%)
Exhibits73: Chart on Geographic comparison
Exhibits74: Data Table on Geographic comparison
Exhibits75: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits107: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits108: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits109: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits110: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits111: Market opportunity by geography ($ million)
Exhibits112: Data Tables on Market opportunity by geography ($ million)
Exhibits113: Impact of drivers and challenges in 2022 and 2027
Exhibits114: Overview on Criticality of inputs and Factors of differentiation
Exhibits115: Overview on factors of disruption
Exhibits116: Impact of key risks on business
Exhibits117: Vendors covered
Exhibits118: Matrix on vendor position and classification
Exhibits119: AbbVie Inc. – Overview
Exhibits120: AbbVie Inc. – Product / Service
Exhibits121: AbbVie Inc. – Key news
Exhibits122: AbbVie Inc. – Key offerings
Exhibits123: Arcutis Biotherapeutics Inc. – Overview
Exhibits124: Arcutis Biotherapeutics Inc. – Product / Service
Exhibits125: Arcutis Biotherapeutics Inc. – Key offerings
Exhibits126: Bausch Health Co. Inc. – Overview
Exhibits127: Bausch Health Co. Inc. – Business segments
Exhibits128: Bausch Health Co. Inc. – Key news
Exhibits129: Bausch Health Co. Inc. – Key offerings
Exhibits130: Bausch Health Co. Inc. – Segment focus
Exhibits131: Bristol Myers Squibb Co. – Overview
Exhibits132: Bristol Myers Squibb Co. – Product / Service
Exhibits133: Bristol Myers Squibb Co. – Key news
Exhibits134: Bristol Myers Squibb Co. – Key offerings
Exhibits135: Eli Lilly and Co. – Overview
Exhibits136: Eli Lilly and Co. – Product / Service
Exhibits137: Eli Lilly and Co. – Key offerings
Exhibits138: Evelo Biosciences Inc. – Overview
Exhibits139: Evelo Biosciences Inc. – Product / Service
Exhibits140: Evelo Biosciences Inc. – Key offerings
Exhibits141: Galderma SA – Overview
Exhibits142: Galderma SA – Product / Service
Exhibits143: Galderma SA – Key news
Exhibits144: Galderma SA – Key offerings
Exhibits145: Incyte Corp. – Overview
Exhibits146: Incyte Corp. – Product / Service
Exhibits147: Incyte Corp. – Key offerings
Exhibits148: LEO Pharma AS – Overview
Exhibits149: LEO Pharma AS – Business segments
Exhibits150: LEO Pharma AS – Key offerings
Exhibits151: LEO Pharma AS – Segment focus
Exhibits152: Maruho Co. Ltd. – Overview
Exhibits153: Maruho Co. Ltd. – Product / Service
Exhibits154: Maruho Co. Ltd. – Key offerings
Exhibits155: Novartis AG – Overview
Exhibits156: Novartis AG – Business segments
Exhibits157: Novartis AG – Key offerings
Exhibits158: Novartis AG – Segment focus
Exhibits159: Otsuka Holdings Co. Ltd. – Overview
Exhibits160: Otsuka Holdings Co. Ltd. – Business segments
Exhibits161: Otsuka Holdings Co. Ltd. – Key offerings
Exhibits162: Otsuka Holdings Co. Ltd. – Segment focus
Exhibits163: Pfizer Inc. – Overview
Exhibits164: Pfizer Inc. – Product / Service
Exhibits165: Pfizer Inc. – Key news
Exhibits166: Pfizer Inc. – Key offerings
Exhibits167: Sanofi SA – Overview
Exhibits168: Sanofi SA – Business segments
Exhibits169: Sanofi SA – Key news
Exhibits170: Sanofi SA – Key offerings
Exhibits171: Sanofi SA – Segment focus
Exhibits172: Viatris Inc. – Overview
Exhibits173: Viatris Inc. – Business segments
Exhibits174: Viatris Inc. – Key offerings
Exhibits175: Viatris Inc. – Segment focus
Exhibits176: Inclusions checklist
Exhibits177: Exclusions checklist
Exhibits178: Currency conversion rates for US$
Exhibits179: Research methodology
Exhibits180: Validation techniques employed for market sizing
Exhibits181: Information sources
Exhibits182: List of abbreviations



★調査レポート[アトピー性皮膚炎治療薬のグローバル市場2023~2027:経口、外用、注射] (コード:IRTNTR75242-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[アトピー性皮膚炎治療薬のグローバル市場2023~2027:経口、外用、注射]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆